CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Kalaris Therapeutics Q3 net loss narrows 7% to $11.03 million

By Public Technologies
  • Kalaris Therapeutics’ third-quarter 2026 net loss narrowed 7% year over year to $11.03 million.
  • Research and development expenses fell 9% year over year to $8.34 million, primarily due to lower manufacturing and process development activity.
  • Cash, cash equivalents and marketable securities totaled $82.86 million at September 30, 2026, with operations expected to be funded into 2028.
  • Preliminary TH103 Phase 1b/2 data are now expected in the second half of 2027 following a clinical-supply interruption.
  • Potential Phase 3 initiation is now expected in 2028; commercial-scale manufacturing technology transfer was completed, with test batches meeting target specifications.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100730PRIMZONEFULLFEED9873823) on November 10, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk